Sugi Predict

Sugi Predict / Compounds / SCHEMBL4884441

SCHEMBL4884441

SCHEMBL4884441

O=C1CCN(Cc2ccncc2)CC1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HPGD P15428 1/20 0.50
▸ LSS P48449 1/20 0.50
▸ KDM4E B2RXH2 4/20 0.49
▸ CYP3A4 P08684 2/20 0.49
▸ CYP2D6 P10635 2/20 0.49
▸ CYP2C9 P11712 2/20 0.49
▸ MEN1 O00255 2/20 0.49
▸ KMT2A Q03164 2/20 0.49
▸ HIF1A Q16665 1/20 0.49
▸ POLB P06746 1/20 0.48
▸ TNKS O95271 1/20 0.47
▸ PARP1 P09874 1/20 0.47
▸ PARP10 Q53GL7 1/20 0.47
▸ TNKS2 Q9H2K2 1/20 0.47
▸ PARP2 Q9UGN5 1/20 0.47
▸ PARP4 Q9UKK3 1/20 0.47
▸ PARP3 Q9Y6F1 1/20 0.47
▸ DRD2 P14416 1/20 0.47
▸ HRH3 Q9Y5N1 1/20 0.47
▸ TSHR P16473 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8108842 1.00 HPGD (0.50) HPGDLSSKDM4ECYP3A4CYP2D6
SCHEMBL28269086 0.83 LSS (0.66) HPGDLSSKDM4ECYP3A4CYP2D6
SCHEMBL8356766 0.81 HRH3 (0.68) CYP3A4MEN1KMT2APOLBHRH3
SCHEMBL4726 0.80 SIGMAR1 (0.68) MEN1KMT2APOLBSIGMAR1
SCHEMBL3994683 0.79 HRH3 (0.67) HPGDLSSKDM4ECYP3A4CYP2D6
SCHEMBL8099601 0.79 CHRNB2 (0.70) KDM4EDRD2ALDH1A1OPRL1CASP1
SCHEMBL1830945 0.79 CHRNB2 (0.70) KDM4EDRD2ALDH1A1OPRL1CASP1
SCHEMBL941871 0.78 KDM4E (0.62) LSSKDM4EMEN1KMT2AHRH3
Hydrochloric Acid SCHEMBL5671727 0.78 SIGMAR1 (0.65) MEN1KMT2APOLBSIGMAR1
Iodide SCHEMBL1697595 0.78 SIGMAR1 (0.65) MEN1KMT2APOLBSIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12403137-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2025-09-02 — — US disclosed
US-11986471-B2 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2024-05-21 — — US disclosed
CN-117304708-A Heptamethine indole cyanine dye and preparation method and application thereof 中国乐凯集团有限公司 2023-12-29 — — CN disclosed
US-20230060499-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-20230060499-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2023-03-02 — — US disclosed
US-20230054084-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2023-02-23 — — US disclosed
US-20230054084-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2023-02-23 — — US disclosed
US-11077101-B1 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2021-08-03 — — US disclosed
US-11077101-B1 Compounds and methods of use TANGO THERAPEUTICS, INC. (US) 2021-08-03 — — US disclosed
WO-2021086879-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. (US) 2021-05-06 — — WO disclosed
US-20080176883-A1 Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone ABBVIE INC. 2008-07-24 — — US disclosed
CN-1604893-A Cyclic amine compound KOWA CO (JP) 2005-04-06 — — CN disclosed
CN-1143858-C 6, 9-disubstituted 2- [ trans- (aminocyclohexyl) amino ] purines, compositions and uses thereof ������ҩ�����޹�˾ 2004-03-31 — — CN disclosed
US-6642231-B2 Antineoplastic agents, treatment for neuronal injury and degeneration AVENTIS PHARMACEUTICALS INC. 2003-11-04 — — US disclosed
EP-1056744-B1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMA INC (US) 2003-10-22 — — EP disclosed
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines AVENTISUB II INC. 2003-06-05 — — US disclosed
US-6479487-B1 INHIBIT CYCLIN DEPENDENT KINASES, PARTICULARLY CDK-2; ANTIAPOPTOSIS AGENT; INHIBITS DEVELOPMENT OF NEOPLASMS AVENTIS PHARMACEUTICALS INC. 2002-11-12 — — US disclosed
CN-1292789-A 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines AWANDIS PHARMACEUTICAL CORP (US) 2001-04-25 — — CN disclosed
EP-1056744-A1 6,9-DISUBSTITUTED 2- TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES Aventis Pharmaceuticals Inc. (US) 2000-12-06 — — EP disclosed
WO-1999043675-A1 6,9-DISUBSTITUTED 2-[TRANS-(4- AMINOCYCLOHEXYL) AMINO]PURINES AVENTIS PHARMACEUTICALS INC. (US) 1999-09-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176883-A1 Antiinflammtory, antiproliferative, anticancer agents; (3-Hydroxy-pyrrolidin-1-yl)-(3-trifluoromethyl-7,8-dihydro-5H-[1,6]naphthyridin-6-yl)-methanone MIF, CCL5, CCR2 HPGD 65/4885LSS 2517/4885KDM4E 3630/4885
US-11986471-B2 Compounds and methods of use XDH, F12, LPXN HPGD 1329/4885LSS 473/4885KDM4E 3697/4885
US-20030105098-A1 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines CDK6, CDK5, CDK2 HPGD 2130/4885LSS 4211/4885KDM4E 990/4885
US-12403137-B2 Compounds and methods of use XDH, LPXN, F12 HPGD 1064/4885LSS 242/4885KDM4E 3468/4885
US-11077101-B1 Compounds and methods of use XDH, F12, LPXN HPGD 1329/4885LSS 473/4885KDM4E 3697/4885
US-20230054084-A1 COMPOUNDS AND METHODS OF USE XDH, LPXN, F12 HPGD 1064/4885LSS 242/4885KDM4E 3468/4885
US-20230060499-A1 COMPOUNDS AND METHODS OF USE XDH, F12, LPXN HPGD 1329/4885LSS 473/4885KDM4E 3697/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.